High plasma phospholipase A 2 activity, inflammation markers, and LDL alterations in obesity with or without type 2 diabetes

Obesity

Volumn 18, Issue 10, 2010, Pages 2023-2029

  Garces, Fatima ^a,b   López, Flor ^b   Nĩo, Cladimar ^b   Fernandez, Anazita ^b   Chacin, Luis ^c   Hurt Camejo, Eva ^d   Camejo, Germán ^d   Apitz Castro, Rafael ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^c Hospital Vargas de Caracas   (Venezuela)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CALCIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PROTEOGLYCAN;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REFERENCE VALUE;

ADULT; AGED; BIOLOGICAL MARKERS; CALCIUM; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; OBESITY; PHOSPHOLIPASES A2; PROTEOGLYCANS; REFERENCE VALUES;

EID: 77957122541     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.9     Document Type: Article

References (31)

1. Boyanovsky BB, Webb NR. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther 2009;23:61-72.
2. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 2009;23:73-83.
3. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009;23:93-101.
4. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999;274:25913-25920.
5. Sartipy P, Johansen B, Gsvik K, Hurt-Camejo E. Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions. Circ Res 2000;86:707-714.
6. Hakala JK, Oörni K, Pentikäinen MO, Hurt-Camejo E, Kovanen PT. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001;21:1053-1058.
7. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 2002;3:3-9.
8. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-1844.
9. Ishimoto Y, Yamada K, Yamamoto S, et al. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta 2003;1642:129-138.
10. Krakoff J, Funahashi T, Stehouwer CD, et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003;26:1745-1751.
11. Paradis ME, Hogue MO, Mauger JF, et al. Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL. Int J Obes (Lond) 2006;30:1615-1622.
12. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006;48:396-401.
13. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoproteinassociated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-437.
14. Iwase M, Sonoki K, Sasaki N, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 2008;196:931-936.
15. Wootton PT, Stephens JW, Hurel SJ, et al. Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus. Atherosclerosis 2006;189:149-156.
16. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007;27:1177-1183.
17. Camejo G, Cortez MM, López C, Mosquera B. Photometric measurement of lipoprotein-cholesterol after agarose electrophoresis: comparison with single-spin ultracentrifugal analysis. Clin Chim Acta 1981;111:239-245.
18. Gleeson M, Kinlay S. Choice of anticoagulant affects measurement of plasma fibrinogen. Clin Chem 1993;39:1754-1755.
19. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
20. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated highsensitivity C-reactive protein assay. Clin Chem 1999;45:2136-2141.
21. Leslie CC, Gelb MH. Assaying phospholipase A2 activity. Methods Mol Biol 2004;284:229-242.
22. Singer AG, Gomaschi F, Le Calvez C, et al. Interfacial Kinetics and Binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002;277:48535-48549.
23. Smart BP, Pan YH, Weeks AK, et al. Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structureguided study. Bioorganic Med Chem 2004;12:1737-1749.
24. Davidsson P, Hulthe J, Fagerberg B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 2005;46:1999-2006.
25. Wootton PT, Drenos F, Cooper JA, et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet 2006;15:355-361.
26. Tannock LR, Chait A. Lipoprotein-matrix interactions in macrovascular disease in diabetes. Frontiers Bioscience 2004;9:1728-1742.
27. Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000;11:465-471.
28. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol 2008;28:1982-1988.
29. Hanasaki K, Yamada K, Yamamoto S, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 2002;277:29116-29124.
30. Karabina SA, Brochériou I, Le Naour G, et al. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J 2006;20:2547-2549.
31. Divchev D, Grothusen C, Lutchfeld M, et al. Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl glutaryl- CoA -reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J 2008;29:1956-1965.